UNSPSC 85812136: Introduction of oxazolidinones into nose, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of oxazolidinones into nose, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E09328

UNSPSC 85812136 Introduction of oxazolidinones into nose, percutaneous approach (Commodity) shows little relevant recent activity in state and local procurement. The code's clinical scope—pharmaceutical administration via intranasal injection—does not align with the posted opportunities tagged under it. Recent solicitations attributed to this code span telehealth urgent care services (Inland Empire Health Plan, RFI, October 31, 2026), comprehensive occupational health and medical director services (DeKalb County, Georgia; Sarasota County, Florida), Program of All Inclusive Care for the Elderly operations (Nevada Health Authority, RFP, December 10, 2026), and diverse health services including cancer registry, employee wellness platforms, and opioid use disorder treatment programs. None of these solicitations involve intranasal medication administration or the pharmaceutical delivery mechanism the code describes.

The mismatch between the code's nominal scope and the actual work being solicited suggests either systematic miscoding of health services procurements at the Commodity level or that this code is rarely used for genuine state and local pharmaceutical delivery contracting. Geographic activity spans California, Georgia, Nevada, Florida, Colorado, and Texas across county health systems, state departments, and regional health authorities. If your firm pursues pharmaceutical-administration services for state or local health systems, verify the correct UNSPSC classification before bidding; this code does not currently reflect actual market activity worth tracking.